Monday, 16 November 2026Follow on 𝕏

Deals Page 4

Deals

AbbVie deepens immunology push with $10.9bn Apogee swoop

AbbVie (ABBV) has agreed to buy Apogee Therapeutics (APGE) for $10.9bn, its largest acquisition in more than five years, as the pharmaceutical group looks to strengthen its pipeline of treatments for inflammatory diseases such as atopic…

Deals

GSK Bets $10.6 Billion on Cancer with Nuvalent Takeover

GSK (GSK) has agreed to acquire U.S.-listed cancer drug developer Nuvalent (NUVL) for $10.6 billion in its largest deal in more than a decade, marking a decisive shift toward oncology under new chief executive Luke Miels as the British…